Abstract:The idea of model-based drug development championed by Lewis Sheiner, in which pharmacostatistical models of drug efficacy and safety are developed from preclinical and available clinical data, offers a quantitative approach to improving drug development and development decision-making. Examples are presented that support this paradigm. The first example describes a preclinical model of behavioral activity to predict potency and time-course of response in humans and assess the potential for differentiation between compounds. This example illustrates how modeling procedures expounded by Lewis Sheiner provided the means to differentiate potency and the lag time between drug exposure and response and allow for rapid decision making and dose selection. The second example involves planning a Phase 2a dose-ranging and proof of concept trial in Alzheimer’s disease (AD). The issue was how to proceed with the study and what criteria to use for a go/no go decision. The combined knowledge of AD disease progression, and preclinical and clinical information about the drug were used to simulate various clinical trial scenarios to identify an efficient and effective Phase 2 study. A design was selected and carried out resulting in a number of important learning experiences as well as extensive financial savings. The motivation for this case in point was the “Learn-Confirm” paradigm described by Lewis Sheiner. The final example describes the use of Pharmacokinetic and Pharmacodynamic (PK/PD) modeling and simulation to confirm efficacy across doses. In the New Drug Application for gabapentin, data from two adequate and well-controlled clinical trials was submitted to the Food and Drug Administration (FDA) in support of the approval of the indication for the treatment of post-herpetic neuralgia. The clinical trial data was not replicated for each of the sought dose levels in the drug application presenting a regulatory dilemma. Exposure response analysis submitted in the New Drug Application was applied to confirm the evidence of efficacy across these dose levels. Modeling and simulation analyses showed that the two studies corroborate each other with respect to the pain relief profiles. The use of PK/PD information confirmed evidence of efficacy across the three studied doses, eliminating the need for additional clinical trials and thus supporting the approval of the product. It can be speculated that the work by Lewis Sheiner reflected in the FDA document titled “Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products” made this scientific approach to the drug approval process possible.

Making good decisions in early drug discovery

Better Decision Making in Drug Development Through Adoption of Formal Prior Elicitation

A Comprehensive Toolbox to Facilitate Quantitative Decision Science in Drug Development: A web-based R shiny application GOahead

Predictive validity in drug discovery: what it is, why it matters and how to improve it

Academic drug discovery: Challenges and opportunities

A data science roadmap for open science organizations engaged in early-stage drug discovery

Implementation and pratical aspects of quantitative decision-making in clinical drug development

DrugGym: A testbed for the economics of autonomous drug discovery

Drug discovery management, small is still beautiful: Why a number of companies get it wrong

How Modeling and Simulation Have Enhanced Decision Making in New Drug Development

Awareness and use of quantitative decision-making methods in pharmaceutical development

Drug discovery and development: introduction to the general public and patient groups

Early Implementation of QbD in Biopharmaceutical Development: A Practical Example

100 Evidence for decision making throughout the product life-span

Disciplined approach to drug discovery and early development

Techniques and Strategies in Drug Design and Discovery

Entering the era of computationally driven drug development

Graph Neural Networks for Drug Discovery: An Integrated Decision Support Pipeline

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation

Unraveling Plant Natural Chemical Diversity for Drug Discovery Purposes

Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action